San Diego—Methylnaltrexone, a peripherally acting μ-opioid receptor (MOR) antagonist, may play a role in slowing tumor progression, new research has found. According to the study, methylnaltrexone influenced cancer progression and prolonged survival in patients with advanced cancer, suggesting that the MOR may be an important therapeutic target.
“Our data suggest that methylnaltrexone used in advanced cancer patients treated with opioids is associated with prolonged